NuPathe raises $30M in venture capital
NuPathe Inc., Conshohocken, says it has raised $30 million in its second round of venture-capital funding.
NuPathe Inc., Conshohocken, says it has raised $30 million in its second round of venture-capital funding.
Major investors include Quaker BioVentures, the Philadelphia-based biotech affiliate of Ira Lubert's Independence Capital Partners, and SR One Ltd., the venture-capital arm of Glaxo SmithKline Plc.
Other funders include Devon-based Safeguard Scientifics Inc., Bay City Capital-Birchmere Ventures of Pittsburgh, Battelle Ventures of Princeton, and Pennsylvania's state-subsidized BioAdvance Ventures, all of which backed NuPathe in its previous fund-raising.
NuPathe said in a statement that it is developing NP101, a skin patch that fights migraine headaches, and NP201, an implant used to treat Parkinson's disease.